Immuron Limited · ASX:IMC
Immuron — Peak Asset Management Sky High Luncheon June 2024
12 slides from Immuron's conference presentation, May 31, 2024
Slide 1: Sky High Luncheon - Steven Lydeamore, CEO
“ : PEAK vy Asser MANAGEMENT: : | t 5 Sky High Luncheon f . Steven Lydeamore Chief Executive Officer a JUNE 2024 . . NASDAQ: IMR \} ASX: > —_
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressio
Slide 3: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview Financial Snapshot Two commercially available oral immunotherapeuti
Slide 4: Bovine colostrum and antibody technology platform
Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to milk. This enables full development of the newb
Slide 5: Bacteria attach to gut wall; neutralized by Travelan antibodies
Bacteria attach to gut wall and infect 10ym200kU S20E3 0003/00 SPECsee Bacteria neutralized by Travelan” antibodies 10 um20.9kU
Slide 6: Status of product portfolio and key milestones
Status of product portfolio and key milestones Travelan® MTEC 21-10-013 grant Phase 2 randomized clinical challenge study to examine a dosing regimen for Travelan® more suited to the military IMM-124E (Travelan®) IND 29087 FDA approval Dec 22 Top-line data 7 March 2024 Anticipated clinical study rep
Slide 7: Travelan market potential and commercial plans
uc PROVEN: Ghrtngom PROTECTION Chief Commercial Officer has USA Marke’ Eval 20+ year's experience with amazon.com shopfront for entry into international local and global (Asia, UK) launched 10FY24 markets commercial leadership roles Exploring re-entry into retail with GSK and P&G pharmacies nYa5 toa
Slide 8: Net Sales A$'000
FY19 FY20 Net Sales AS'000 FY23 YTDMarFY24
Slide 9: Phase 2 CHIM study design
Healthy volunteers were recruited and randomized to receive a single daily oral dose of 1200 mg of Travelan® or placebo. Dosing commenced 2 days prior to challenge with ETEC strain H10407 and continued for 7 days. 60 subjects completed the inpatient challenge component of this current clinical study
Slide 10: IMM-124E Phase 3 strategy
ImM-124E Phase 3 strategy GD ar» Gc» Phase a clinical study Clinical Study Report Phase 3 FDA meeting Initiate Phase 3 Trial duration ~ 2 years (Baltimore, 1996) anticipated July 2024 Estimated trial cost $5 Phase 2 clinical study End of Phase 2 FDA meeting million each trial (Poland, 2000) —— End o
Slide 11: Scientific references
Scientific references Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC- induced diarrhea in up to 90% of volunteers Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 ni 5 ° - 5 , Clinical Evaluation of Travelan
Slide 12: Contact information
IMmmMuUren STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: [4] EMAIL: STEVE@IMMURON.COM a PHONE: AUSTRALIA: +61 438 027 172
Immuron — Peak Asset Management Sky High Luncheon June 2024 on 6ix